These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 22306125

  • 1. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
    Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng CM, Zhou XW.
    Lung Cancer; 2012 Jul; 77(1):9-15. PubMed ID: 22306125
    [Abstract] [Full Text] [Related]

  • 2. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 3. The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis.
    Yang YL, Luo XP, Xian L.
    PLoS One; 2014 Jun; 9(4):e93997. PubMed ID: 24705847
    [Abstract] [Full Text] [Related]

  • 4. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
    Sève P, Isaac S, Trédan O, Souquet PJ, Pachéco Y, Pérol M, Lafanéchère L, Penet A, Peiller EL, Dumontet C.
    Clin Cancer Res; 2005 Aug 01; 11(15):5481-6. PubMed ID: 16061864
    [Abstract] [Full Text] [Related]

  • 5. Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.
    Vilmar AC, Santoni-Rugiu E, Sørensen JB.
    Clin Cancer Res; 2011 Aug 01; 17(15):5205-14. PubMed ID: 21690572
    [Abstract] [Full Text] [Related]

  • 6. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.
    Sève P, Lai R, Ding K, Winton T, Butts C, Mackey J, Dumontet C, Dabbagh L, Aviel-Ronen S, Seymour L, Whitehead M, Tsao MS, Shepherd FA, Reiman T.
    Clin Cancer Res; 2007 Feb 01; 13(3):994-9. PubMed ID: 17289895
    [Abstract] [Full Text] [Related]

  • 7. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA, Schell MJ, Bakri K, Peterman A, Lee JH, Unger P, Yates S, Hudgens S, Kies MS.
    Cancer; 2002 Sep 15; 95(6):1265-73. PubMed ID: 12216094
    [Abstract] [Full Text] [Related]

  • 8. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K, Sasada T, Kawahara A, Hattori S, Kinoshita T, Takamori S, Ichiki M, Imamura Y, Ikeda J, Kage M, Kuwano M, Aizawa H.
    Cancer Chemother Pharmacol; 2009 Aug 15; 64(3):565-73. PubMed ID: 19123003
    [Abstract] [Full Text] [Related]

  • 9. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
    Sève P, Reiman T, Lai R, Hanson J, Santos C, Johnson L, Dabbagh L, Sawyer M, Dumontet C, Mackey JR.
    Cancer Chemother Pharmacol; 2007 Jun 15; 60(1):27-34. PubMed ID: 17021819
    [Abstract] [Full Text] [Related]

  • 10. Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.
    Kosmidis PA, Syrigos K, Kalofonos HP, Dimopoulos MA, Skarlos D, Pavlidis N, Boukovinas I, Bafaloukos D, Pectasides D, Bacoyiannis C, Fountzilas G.
    Anticancer Res; 2012 Jan 15; 32(1):175-81. PubMed ID: 22213304
    [Abstract] [Full Text] [Related]

  • 11. [Class III beta tubulin expression in nonsmall cell lung cancer].
    Sève P, Dumontet C.
    Rev Mal Respir; 2010 Apr 15; 27(4):383-6. PubMed ID: 20403547
    [Abstract] [Full Text] [Related]

  • 12. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
    Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y.
    Lung Cancer; 2008 Oct 15; 62(1):105-12. PubMed ID: 18395930
    [Abstract] [Full Text] [Related]

  • 13. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
    Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D, Rodríguez-Antona C.
    Endocr Relat Cancer; 2011 Feb 15; 18(1):85-95. PubMed ID: 21051560
    [Abstract] [Full Text] [Related]

  • 14. A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer.
    Gao G, Chu H, Zhao L, Gui T, Xu Q, Shi J.
    Lung Cancer; 2012 Jun 15; 76(3):380-6. PubMed ID: 22226626
    [Abstract] [Full Text] [Related]

  • 15. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P, Ortmanns P, Marien S, Degives R, Degraeve D, Potvin M, Grauwels D, Schallier D.
    Anticancer Res; 2001 Jun 15; 21(2B):1487-94. PubMed ID: 11396237
    [Abstract] [Full Text] [Related]

  • 16. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
    Li DX, Chen XB.
    Ai Zheng; 2002 Apr 15; 21(4):412-5. PubMed ID: 12452023
    [Abstract] [Full Text] [Related]

  • 17. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Burris HA, Morrissey LH, Thomas M, Erland JB, Butts JA, Joseph G, Kalman L, Greco FA.
    Cancer J; 2000 Apr 15; 6(3):151-6. PubMed ID: 10882330
    [Abstract] [Full Text] [Related]

  • 18. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions.
    Bunn PA.
    Semin Oncol; 1997 Aug 15; 24(4 Suppl 12):S12-153-S12-162. PubMed ID: 9331142
    [Abstract] [Full Text] [Related]

  • 19. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M, Pereira JR, Temperley G, Negro-Vilar R, Rahal S, Zhang JK, Negro-Vilar A, Dziewanowska ZE.
    J Clin Oncol; 2008 Apr 10; 26(11):1886-92. PubMed ID: 18398154
    [Abstract] [Full Text] [Related]

  • 20. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ, Fernandes AL, Pereira JR, Curtis JR, Santoro IL.
    Lung Cancer; 2006 Aug 10; 53(2):171-6. PubMed ID: 16757059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.